Danaher price target lowered to $220 from $230 at BofA

BofA lowered the firm’s price target on Danaher (DHR) to $220 from $230 and keeps a Buy rating on the shares. While there has been some stabilization and/or improvement in some areas of Life Sciences and Diagnostic Tools, several pockets of uncertainty and softness over the past year remain and are likely to persist for at least the next few quarters, says the analyst, who is trimming forecasts for many core Tools companies and now anticipates a more gradual return to “normal.”